LumiraDx to discuss microfluidic technology at AACC

By LabPulse.com staff writers
July 25, 2022

LumiraDx announced that it will host an industry workshop at AACC 2022 on Wednesday, describing the impact of its microfluidic technology on lateral-flow antigen tests and the role of these rapid immunoassays in the response to the COVID-19 pandemic.

"Studies have shown that point-of-care antigen tests with sufficient sensitivity and specificity can facilitate diagnosis, treatment, and mitigate reliance on slower, conventional laboratory-based testing and infrastructure," Brian DuChateau, vice president of Clinical and Scientific Affairs at LumiraDx, said in a statement. "However, the COVID-19 pandemic not only demonstrated the need for this type of testing, but also showed how quick result turn-around time can mitigate rates of infection."

DuChateau added that LumiraDx's actively controlled microfluidic testing technology brings lab-comparable performance to the point-of-need, "supporting several unique use cases during the pandemic and beyond."

LumiraDx prices $75.3M public offering
Point-of-care diagnostics company LumiraDx on Thursday announced the pricing of its underwritten public offering of 43 million common shares at $1.75...
LumiraDx diabetes test receives CE Mark
Point-of-care diagnostics company LumiraDx recently received the CE mark for its quantitative fingerstick HbA1c test for diabetes screening and monitoring.
LumiraDx COVID antigen test receives CE Mark
LumiraDx’s SARS-CoV-2 Ag Ultra Test recently received the CE Mark, with the company promoting the test’s performance in COVID-19 antigen testing.
LumiraDx reports revenue increases for Q1
Point-of-care diagnostics company LumiraDx reported revenue increases for the first quarter of the 2022 fiscal year, with revenues driven in part by sales...

Copyright © 2022 LabPulse.com

Last Updated 7/25/2022 1:05:33 PM